Hypertension and Angina Management

Introduction to Amlodipine

The American College of Cardiology recommends amlodipine as a first-line treatment for hypertension in most patients, and as a second-line agent for angina when beta-blockers cannot be tolerated or as an add-on therapy when angina persists despite beta-blocker treatment 1

The American College of Cardiology recommends a general target blood pressure of <140/90 mmHg, and <130/80 mmHg for patients with coronary artery disease, diabetes, chronic kidney disease, or coronary artery disease risk equivalents 1
A lower target BP (<130/80 mmHg) may be considered in some individuals with CAD, previous stroke/TIA, or CAD risk equivalents, with a strength of evidence based on clinical trials, as recommended by the American Heart Association and European Heart Society 2, 3, 4
A blood pressure target of <140/90 mmHg is recommended for patients with stable angina, according to the American Heart Association, based on high-quality evidence 4

Beta-blockers are the preferred first-line treatment for angina due to their benefits in reducing heart failure hospitalization and mortality risk, according to the American Heart Association 5
Amlodipine should be considered in patients unable to tolerate a beta-blocker to relieve angina, with a Class IIa recommendation and Level of Evidence A, as suggested by the European Society of Cardiology 6
Amlodipine should be added as a second anti-anginal drug when angina persists despite beta-blocker treatment, with a Class I recommendation and Level of Evidence A, as recommended by the European Society of Cardiology 6

Amlodipine is one of the few calcium channel blockers that can be safely used in patients with heart failure and angina, according to the American College of Cardiology 7
Non-dihydropyridine CCBs (diltiazem, verapamil) should NOT be used in heart failure patients due to their negative inotropic effects and risk of worsening heart failure, as warned by the European Society of Cardiology 6
Amlodipine can be safely used in patients with left ventricular dysfunction, unlike non-dihydropyridine CCBs, as stated by the American Heart Association 8, 4

Amlodipine can be added to the basic regimen of beta-blocker, ACE inhibitor, and thiazide diuretic if either angina or hypertension remains uncontrolled, according to the American College of Cardiology, based on moderate-quality evidence 4
The combination of amlodipine with beta-blockers is safe and effective, unlike the combination of beta-blockers with non-dihydropyridine CCBs, according to the American Heart Association 5
The combination of beta-blockers with non-dihydropyridine CCBs (diltiazem or verapamil) should be used with caution due to risk of bradyarrhythmias and heart failure, based on low-quality evidence, as advised by the American College of Cardiology 4

The initial dose of amlodipine for patients with hypertension or coronary artery disease should be 5 mg once daily, with titration to 10 mg once daily if necessary, according to the European Society of Cardiology and American Heart Association 2, 3, 4
For elderly patients, fragile patients, patients with hepatic insufficiency, or when adding to other antihypertensive therapy, the initial dose of amlodipine should be 2.5 mg once daily, as recommended by the European Society of Cardiology 2
For pediatric patients aged 6-17 years, the dose of amlodipine is 2.5-5 mg once daily, according to the European Society of Cardiology 2

Blood pressure response should be monitored 7-14 days after initiation or dose changes, according to the American Heart Association, with a strength of evidence based on clinical trials 5, 4
Common adverse effects of amlodipine include peripheral edema, headache, flushing, and dizziness, based on high-quality evidence, as reported by the American Heart Association 9, 4
Close monitoring is essential during the initial administration and titration period, with checks for signs of hypotension, such as dizziness and lightheadedness, particularly within the first 1-2 weeks of combination therapy, as advised by the European Society of Cardiology 10
Elderly patients are more susceptible to hypotension and should be started with lower doses of both medications, as recommended by the American Geriatrics Society 10
Volume-depleted patients are at a higher risk of first-dose hypotension, and close monitoring is essential, as advised by the European Society of Cardiology 10
Patients with hepatic dysfunction require careful consideration, as the clearance of nifedipine is reduced in cirrhosis, increasing systemic exposure, according to the European Association for the Study of the Liver 10